HK Stock Market Move | CMS(00867) increased by over 3%. The new drug Luscanatinib paste for innovative medicine has obtained acceptance for a new drug application (NDA) for the AD indication.

CMS (00867) rose more than 3%, as of press time, rose 2.73% to HK$15.41, with a turnover of HK$28.85 million. On the news front, on February 24, CMS announced that its subsidiary, Demei Pharmaceuticals Limited ("Demei Pharmaceuticals"), a innovative pharmaceutical company focusing on skin health, is applying for listing on the main board of the Hong Kong Stock Exchange. The company has received acceptance from the National Medical Products Administration (NMPA) for the new drug listing application (NDA) for phospho-lutinib cream ("product") for mild to moderate atopic dermatitis (AD) on February 24, 2026. The product is intended for short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised children aged 2 and above and adults when other topical drugs are ineffective or not recommended for use. The NDA has been approved by the NMPA Drug Evaluation Center for inclusion in the priority review list for its "new drug varieties, dosage forms, and specifications suitable for children's physiological characteristics." This is expected to accelerate the product's AD indication listing review process. Furthermore, phospho-lutinib cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted therapy approved in China for vitiligo treatment. The acceptance of the new AD indication NDA is a key milestone for the product in expanding into multiple treatment areas.